The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Resistance to RAF- and MEK-targeted therapy is a major clinical challenge(1–4). RAF and MEK inhibitors are initially but only transiently effective in some but not all patients with BRAF gene mutation and are largely ineffective in those with RAS gene mutation because of resistance(5–14). Through a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nat Genet
Hauptverfasser: Lin, Luping, Sabnis, Amit J, Chan, Elton, Olivas, Victor, Cade, Lindsay, Pazarentzos, Evangelos, Asthana, Saurabh, Neel, Dana, Yan, Jenny Jiacheng, Lu, Xinyuan, Pham, Luu, Wang, Mingxue M, Karachaliou, Niki, Cao, Maria Gonzalez, Manzano, Jose Luis, Ramirez, Jose Luis, Torres, Jose Miguel Sanchez, Buttitta, Fiamma, Rudin, Charles M, Collisson, Eric A, Algazi, Alain, Robinson, Eric, Osman, Iman, Muñoz-Couselo, Eva, Cortes, Javier, Frederick, Dennie T, Cooper, Zachary A, McMahon, Martin, Marchetti, Antonio, Rosell, Rafael, Flaherty, Keith T, Wargo, Jennifer A, Bivona, Trever G
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4930244/
https://ncbi.nlm.nih.gov/pubmed/25665005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.3218
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge